Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes (CTLs) 
documented in an infectious disease, yet estimates of CTL frequency derived from limiting-dilution analysis (LDA) are relatively low and comparable to other viral infections. Here we show that individual CTL clones specific for peptides from HIVgag andpol gene products are present at high levels in the peripheral blood of three infected patients and that individual CTL clones may represent between 0.2% and 1% of T cells. Previous LDA in one donor had shown a frequency of CTL precursors of 1/8000, suggesting that LDA may underestimate CTL effector frequency. In some donors individual CTL clones persisted in vivo for at least 5 years. In contrast, in one patient there was a switch in CTL usage suggesting that different populations of CTLs can be recruited during infection. These data imply strong stimulation of CTLs, potentially leading some clones to exhaustion.
Human immunodeficiency virus (HIV) infection is associated with a very strong cytotoxic T cell (CTL) response to viral peptides (1) (2) (3) . Many CTL epitopes have been characterized and are presented in association with a variety of HIA alleles (4) . A feature of HIV-specific cytotoxicity is that many donors show such activity in fresh peripheral blood without the need for in vitro stimulation to expand the number of virus-specific CTLs (2) . This phenomenon of "fresh killing" suggests that the number of virus-specific CTLs in peripheral blood is high, and estimates derived from comparisons with cytotoxicity of similar magnitude by influenza-specific CTL lines have suggested that around 2% of all CD8+ T cells would need to be CTLs with specificity for HIV (5) .
Many studies of limiting-dilution analysis (LDA) for CTLs in HIV infection have been performed and have generally revealed CTL precursor frequencies of between 1/1000 and 1/100,000 (5) (6) (7) . A previous LDA on one of our donors, 007, who makes an HLA-B27-restricted Gag-specific response, suggested a CTL precursor frequency of 1/8000 (5) . Here we use the T-cell antigen receptor (TCR complementaritydetermining region 3 (CDR3) sequencesl as molecular markers for individual CTL clones and estimate the frequency of HIV-specific CTLs in the peripheral blood of infected hemophiliac donors. Results show high levels of CTLs in peripheral blood lymphocytes (PBLs), more in agreement with previous functional assays than with LDAs. There may therefore be a discrepancy between the number of CTL precursors as measured by LDA and the number of differentiated effector CTLs.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
It has been suggested that HIV-specific CTL clones may have a limited lifespan in vivo due to excessive stimulation from the high viral load (8) . A recent report has documented the survival of a single HLA-B14-restricted HIV-specific CTL clone for 31 months (9 (10) , whereas the line from 008 was specific for the nonapeptide 309-317 from HIV reverse transcriptase presented by HLA-A2 (11, 12) (Table 1) . "Bulk cultures" were established from peripheral blood mononuclear cells and CTL lines were grown from these cultures by using autologous irradiated B-lymphoblastoid lines pulsed with the appropriate peptide at 50 ,uM (10) . Standard 4-hr cytotoxicity assays were carried out with autologous or HLA-matched B-lymphoblastoid cells pulsed with peptide at 10 ,uM (10) . The lines were cultured in vitro until they lysed autologous peptide-pulsed B cells with high specificity and sensitivity.
Generation of HIV-Specific CTL Clones. CTLs from established HIV-specific lines were diluted into flat-bottomed 96-well plates (Nunc) at 0.3 cell per well in 100 ,lI of cloning mixture consisting of 104 autologous, irradiated (2000 rads; 1 rad = 0.01 Gy) peptide-pulsed B cells together with 105 mixed irradiated (3000 rads) freshly separated allogeneic lymphocytes from at least three donors in RPMI 1640 medium with 10% fetal bovine serum and phytohemagluttinin (Wellcome) at a final concentration of 5 ,&g/ml (13) . A further 100 ,ul of RPMI 1640/10% fetal bovine serum, supplemented with 20% Lymphocult-T (Biotest), was added on day 4. After 2 weeks, positive wells were identified and the cells were expanded into 24-well tissue culture plates in a further 1 ml of cloning mixture. Lymphocult-T was added after 3 days and the clones were tested for specific cytotoxic activity when expanded into After sequencing, an oligonucleotide was designed which was complementary to the sequence encoding CDR3 of the TCR 13 chains. To assess the frequency of individual CTLs in the peripheral blood of the donors, fresh PBLs were isolated and, following RNA extraction and cDNA synthesis, a TCR 13 amplification was performed by anchored PCR. PCR products were cloned into M13mp18 and used to transform E. coli so that >6000 plaques were isolated in each case. Plaques were then hybridized first to an oligonucleotide complementary to the TCR 3 constant domain (5'-CGACCTCGGGTGGGAA-CAC-3') and then to an oligonucleotide specific for the TCR 13 chain from the CTL clone or line of the individual donor (see Fig. 2 ). Positive plaques were counted. Positive hybridizing clones were then sequenced in order to verify that hybridization was specific for the original TCR 3 transcript. TCR amplification products from PBLs of donors who were both HLA-B27+ and HLA-A2+ but HIV-seronegative were hybridized with the CDR3-specific oligonucleotides to check that the CDR3 sequences were not common in HIV-seronegative donors, and no positively hybridizing plaques were seen (data not shown). To test whether or not increased TCR mRNA levels in stimulated CTLs might lead to an overestimation of CTL precursor frequencies, resting PBLs were "spiked" with an influenza nucleoprotein-specific HLA-B27-restricted CTL clone which had been maintained in vitro and whose TCR 13 sequence had been determined. After mixing at a CTL/PBL ratio of 1:100, plaque hybridization with an oligonucleotide complementary to the CDR3 sequence (5'-GTCCCCCCCG-TATCTTG-3') gave a precursor frequency of 1 in 20, showing that the method could overestimate the CTL frequency by up to 5-fold. This correction factor was used in calculation of CTL precursor frequencies in patients. As a further control an oligonucleotide was designed which was complementary to the CDR3 sequence of an Epstein-Barr virus-specific CTL clone derived from another donor (5'-TCCCGCGTCCCT-GCTCTA-3'), and the precursor frequency in PBLs was determined.
RESULTS AND DISCUSSION
CTLs Were Detected in All Donors. CTL lines specific for the dominant p24 epitope 265-274 (p24-14) presented by HLA-B2705 were raised from PBLs of donors 007 and 049 and recognized peptide with high specificity (Fig. 1) in the CDR3 sequences of the two transcripts. Given the high peptide specificity of these lines at low effector/target cell ratios (70% lysis at a 2:1 killer/target ratio; data not shown), we can assume that the bulk of the CTL activity was due to clones expressing these receptors. This assumption is further strengthened by the finding that the percent contribution of transcripts 007B1 and 049B1 increased as the CTL lines were cultured in vitro and became more peptide-specific (Fig. 3B) . TCR a-chain transcripts in both lines were also oligoclonal. The three TCR clones obtained from line 0492 (049B2-4) all utilized Vp12.4 and showed a high degree of homology in CDR3, in a pattern typical of TCR conservation in the recognition of class I-restricted peptides (17, 18) (Fig. 3) . None of these clones had been present in the initial CTL line 0491, whereas transcript 049B1 from that line was not detected in the 0492 line. Therefore, there appears to have been a change in CTL usage over time in this donor.
The two CTL clones obtained from donor 008 expressed a V,p1 or a Vp21 transcript, respectively (008B1 and -2, Fig. 2 ).
Both sequences were present in CTL lines 008, and 0082.
All CTL lines were class I HLA-restricted and assumed therefore to be CD8+.
Quantitation of Individual CTL Clones Within Peripheral Blood. Anchored PCR has been shown to be a quantitative technique (14, 19) , and characterization of TCR (3-chain expression of the T-cell clones allowed analysis of the frequency of the clones in the peripheral blood of the donors (Table 2) The highest frequency obtained was for sequence 007B1, which was found at a frequency of 1/110 of all TCR transcripts derived from the peripheral blood of donor 007 taken in 1991.
When corrected for the CD4+/CD8+ ratio this corresponds to a maximum frequency within the CD8+ population of 1/77 (1.3%). Two years later the corresponding values were 1/105 and 1/76, respectively. The lower limit of frequency, if we assume that TCR 3 mRNA levels are increased in activated CTLs, is -0.2% of T cells, still much higher than detected by LDAs. Sequence 049B1 was also found at a high frequency, representing 1/191 transcripts in peripheral blood from donor 049, equivalent to 1/129 CD8+ cells. With correction for possible mRNA bias, this would correspond to at least 1/1000 T cells or 1/600 CD8+ T cells. At the second time point when peripheral blood from donor 049 was sampled, 1993, the combined frequency of the transcripts 049B2-4 was 1/636, a fall from the frequency of 049B1 in blood from 1992. Transcripts from the CTL clones of donor 008 (008B1 and 008B2) were found at a combined frequency of 1/465 in November 1992.
To assess the longevity of the CTL clone expressing 007B1, the TCR usage of p24-14-specific CTL lines from donor 007 isolated between 1989 and 1994 was studied; the 007B1 sequence was found in all lines, showing that this CTL clone had persisted in the donor for at least 5 years. The percentage contribution of the 007B1 transcript in all TCRs isolated from each line varied at the different time points but, as newly generated HIV-specific CTL lines contain nonspecifically activated T cells, anchored PCR will clone irrelevant TCR sequences (data not shown) and thus would lead to an underestimation of the true contribution of 007B1 to the true cytotoxic activity in the CTL line.
As many asymptomatic HIV-seropositive donors show HIVspecific CTL lysis in fresh, unstimulated PBLs without the need for secondary in vitro stimulation (2, 20, 21) , it might be expected that the precursor frequency of HIV-specific CTLs is very high. PBLs from donor 007 regularly lyse p24-14-pulsed target cells with a specific lysis activity of 30% at a PBL/target ratio of 25:1 (ref. 5 and data not shown). CTL clones derived from donor 049 which recognize the same epitope give this level of lysis at killer/target ratios of 0.1-1.0:1. These data imply that the frequency of effector CTLs in fresh PBLs must be between 1/250 and 1/25, in line with the upper limit clonal frequency estimates derived from the TCR (3 transcript frequencies. However, LDA of HIV-specific CTLs from donor 007 done from a blood sample that exhibited fresh killing of target cells gave a precursor frequency of 1/8000 (5). Several other groups have reported similar precursor frequencies in HIV, in the range of 1/2000 to 1/20,000 (7, 20) , even in the presence of fresh killing. However, Kalams et al. (9) found a precursor frequency of 1/1016 for an individual clone recognizing the gp4l peptide restricted by HLA-B14 (9), using a CD3-specific monoclonal antibody for T-cell stimulation. Our data, based on the frequency of TCR (3 transcripts from CTL clones and lines specific for HIV peptide epitopes, reveal frequencies that are both much higher than suggested by LDA and higher than previously documented in human immune responses. Although the LDA on donor 007 was not performed on the same blood samples that were analyzed in this work, the level of killing by CTLs restimulated in vitro and by fresh CTLs has remained remarkably stable between 1987 and 1994 (22) , and the samples are likely to be comparable. The discrepancy between our figures and data derived from LDA may reflect an inability of a population of effector CTLs to proliferate in vitro, so that such cells do not expand in the LDA. Indeed, CD8+ T lymphocytes have been shown to have defective clonogenic potential in patients with AIDS (23) . It is intriguing that, using methods that have been highly successful in other donors, we failed in five attempts to generate CTL clones from donor 007 despite the particularly strong and persistent CTL response generated against the p24-14 peptide. The finding that unstimulated PBLs can show fresh HIV-specific lysis suggests that our estimates of effector CTL frequency are more representative than the figures obtained from LDA, which may more accurately document the memory population.
The high frequency of CTL effectors implies strong antigenic stimulation. Estimates of HIV-specific memory CTLs from LDA show a fall during progression of disease (7, 24) , and memory CTL exhaustion may be a consequence of chronic viral stimulation leading to overexpansion of terminally differentiated CTLs and loss of the memory pool (25) .
The reduction in HIV-specific CTLs in the late stages of HIV infection may result in a failure to contain the virus (24) . Experiments with mice have shown that CTLs specific for lymphocytic choriomeningitis virus can become exhausted following high-multiplicity viral infection (25) , and this has led to suggestions that HIV-specific CTL clones can similarly become exhausted by chronic stimulation and therefore have a limited lifespan (8) . The progeny of one HIV gp4l-specific CTL clone were detected over a 31-month time course (9) , and our data also show that a single CTL clone can persist in vivo for at least 5 years. The two clones isolated from donor 008 have also persisted for 30 months to date. Previous reports have also documented long-term in vivo persistence of house dust mite-or heat shock protein-specific CD4+ T-cell clones in seronegative donors (26, 27) .
As the 007B1 and 008B1 and -2 transcripts were continually detected in antigen-specific CTL lines, it is clear that the clones maintained cytotoxic activity. Indeed, 007B1 made the major contribution to CTL lines in 1991 and 1994, showing that the immune response to a single peptide can be dominated by a single CTL clone rather than many different T cells. The recognition of p24-14 peptide provides most or all of the fresh killing response seen in donor 007, since it has not been possible to detect any other CTL specificity. Thus a major proportion of the CTL response to the whole virus in this patient may be from this one clone. It is also possible that not all class I-restricted cells were cytotoxic and that they may have possessed other functions, such as secretion of cytokines.
The persistence of the 007B1 clone may be helped by the low rate of mutation in this epitope in this patient (22 
